TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25966781

Group type: COMPARATOR
Intervention: OZ439 alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: OZ439 plus PQP (800 mg OZ439 with 960 mg PQP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: OZ439 plus PQP (800 mg OZ439 with 1440 mg PQP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Piperaquine
Number of subjects: 59
Study: 23680067

Group type: EXPERIMENTAL
Intervention: Multiple-traffic-light GDA system
Number of subjects: 81

Group type: COMPARATOR
Intervention: Monochrome GDA system
Number of subjects: 81
Study: 21777435

Group type: EXPERIMENTAL
Intervention: Revised Patient Information Sheet (PIS)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Original Patient Information Sheet (PIS)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Preference for PIS version
Number of subjects: 123
Study: 19304086

Group type: EXPERIMENTAL
Intervention: Aspheric AcrySof SN60WF IOL
Number of subjects: 2

Group type: COMPARATOR
Intervention: Spherical AcrySof SN60AT IOL
Number of subjects: 2
Study: 17236636

Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion (TCI) with noxious stimulus (hand immersion in cold water at 2-4 degrees C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Remifentanil TCI infusion added to propofol TCI anesthesia
Number of subjects: 20
Study: 12771852

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (2 tablets/day for 6 months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Compression therapy alone (Control group)
Number of subjects: 150
Study: 10950232

Group type: EXPERIMENTAL
Intervention: Teaching mothers to provide chloroquine to their sick children at home
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (community health worker approach)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Verbal autopsy in intervention tabias
Number of subjects: 70

Group type: COMPARATOR
Intervention: Verbal autopsy in control tabias
Number of subjects: 70
Study: 8812724

Group type: EXPERIMENTAL
Intervention: Chronic sodium benzoate (SB) therapy
Number of subjects: 16
Study: 1579871

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional disc surgery
Number of subjects: 92
Study: 4084669

Group type: EXPERIMENTAL
Intervention: Allopurinol tablets 100 mg, DAK
Number of subjects: 11

Group type: COMPARATOR
Intervention: Apurin tablets 100 mg, Gea
Number of subjects: 11
Study: 31085305

Group type: EXPERIMENTAL
Intervention: NIH response measures
Number of subjects: 488
Study: 30205427

Group type: EXPERIMENTAL
Intervention: Carnosine 2 g
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 27049809

Group type: EXPERIMENTAL
Intervention: 3.0% diquafosol tetrasodium ophthalmic solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 34
Study: 24976433

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg as selenomethionine)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 23089999

Group type: EXPERIMENTAL
Intervention: Low-GI legume diet
Number of subjects: 121

Group type: COMPARATOR
Intervention: High wheat fiber diet
Number of subjects: 121
Study: 20880348

Group type: EXPERIMENTAL
Intervention: Sodium tungstate (100 mg bid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sodium tungstate
Number of subjects: 30
Study: 18024853

Group type: EXPERIMENTAL
Intervention: GW501516 (10 mg o.d.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: GW590735 (20 mug o.d.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16005162

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Morphine (50 mg and 25 mg)
Number of subjects: 22
Study: 15384293

Group type: EXPERIMENTAL
Intervention: 30-70% nitrous oxide (N2O)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.2-0.8% sevoflurane
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both N2O and sevoflurane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.7% end tidal sevoflurane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: N2O and sevoflurane
Number of subjects: 22
Study: 10099142

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 8523053

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tamoxifen and Toremifene
Number of subjects: 24
Study: 1779028

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients (AD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Elderly control subjects (EC)
Number of subjects: 22
Study: 7015221

Group type: EXPERIMENTAL
Intervention: BW146Y
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BW29Y
Number of subjects: 0

Group type: COMPARATOR
Intervention: BW146Y and BW29Y
Number of subjects: 0
Study: 31204417

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for malignant lesions
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for benign lesions
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for hepatocellular carcinoma
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for hemangioma
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for metastases
Number of subjects: 2062
Study: 28891777

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 140

Group type: COMPARATOR
Intervention: Behavioral counseling
Number of subjects: 140
Study: 26510851

Group type: EXPERIMENTAL
Intervention: Treadmill exercise: 150 or 300 min/week for five menstrual cycles
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group: maintained exercise <75 min/week
Number of subjects: 139
Study: 23930552

Group type: EXPERIMENTAL
Intervention: Guided perceptual-training group (n = 9)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Unguided perceptual-training group (n = 10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 28
Study: 21893709

Group type: EXPERIMENTAL
Intervention: Mentor plus mobile phone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mentor-only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 19218306

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 200
Study: 17868721

Group type: EXPERIMENTAL
Intervention: Higher body mass index in androgen dependent disease
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Increasing body mass index in androgen dependent disease
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Body mass index in androgen independent disease
Number of subjects: 1677
Study: 19753736

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 60
Study: 10608651

Group type: EXPERIMENTAL
Intervention: Active Virtual Environment (VE) participation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Passive Virtual Environment (VE) participation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Passive control participation
Number of subjects: 48
Study: 7851592

Group type: EXPERIMENTAL
Intervention: Mini-Percoll separation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Direct swim-up separation
Number of subjects: 30

Group type: COMPARATOR
Intervention: SpermPrep filtration column
Number of subjects: 30
Study: 1942422

Group type: EXPERIMENTAL
Intervention: Zidovudine 1200 mg daily (protocol 016)
Number of subjects: 2048

Group type: EXPERIMENTAL
Intervention: Zidovudine 500 mg daily (protocol 019)
Number of subjects: 2048

Group type: EXPERIMENTAL
Intervention: Zidovudine 1500 mg daily (protocol 019)
Number of subjects: 2048

Group type: EXPERIMENTAL
Intervention: Zidovudine (any dosage)
Number of subjects: 2048

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2048
Study: 6791868

Group type: EXPERIMENTAL
Intervention: X-Prep liquid with colonic washout
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral mannitol alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral mannitol with colonic washout
Number of subjects: 60
Study: 31711752

Group type: EXPERIMENTAL
Intervention: ABI-H0731 100 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ABI-H0731 200 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ABI-H0731 300 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ABI-H0731 (various doses)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ABI-H0731
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 30968678

Group type: EXPERIMENTAL
Intervention: Lertal + standard treatment
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo + standard treatment
Number of subjects: 146
Study: 28660990

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy (Michigan splint) for 30 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: External jugular vein venepuncture
Number of subjects: 39
Study: 25100052

Group type: EXPERIMENTAL
Intervention: Daily alcohol use
Number of subjects: 0
Study: 23303903

Group type: EXPERIMENTAL
Intervention: Ginger (2.0 g daily for 28 days)
Number of subjects: 20
Study: 21676960

Group type: EXPERIMENTAL
Intervention: Child-rated scale
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Parent-rated scale
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Theorized factor structure
Number of subjects: 403
Study: 18930094

Group type: EXPERIMENTAL
Intervention: PfCP2.9/ISA 720 (5, 20, and 50 microg)
Number of subjects: 70
Study: 16540287

Group type: EXPERIMENTAL
Intervention: Meloxicam 10 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ampiroxicam 27 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 15451148

Group type: EXPERIMENTAL
Intervention: HF (Heart Failure)
Number of subjects: 15078
Study: 10419345

Group type: EXPERIMENTAL
Intervention: Biopsy of normal-appearing urothelium in low-risk tumors
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Biopsy of normal-appearing urothelium in intermediate- and high-risk tumors
Number of subjects: 995
Study: 7742745

Group type: EXPERIMENTAL
Intervention: rhu EPO (300 units per kg/day given thrice weekly by intravenous injection)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no rhu EPO)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: rhu EPO group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: rhu EPO
Number of subjects: 91
Study: 2285274

Group type: EXPERIMENTAL
Intervention: Rimantadine (100 mg daily)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 7433474

Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline daily for 10 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline on the first day and 100 mg on subsequent days for 8 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 46
Study: 30707360

Group type: EXPERIMENTAL
Intervention: Natural cycle with spontaneous ovulation
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Natural cycle with hCG for ovulation induction
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Hormone replacement cycle (HRC)
Number of subjects: 471
Study: 30208454

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam, 4.5 g, every 6 hours (n=188 participants)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Meropenem, 1 g, every 8 hours (n=191 participants)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 391

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 391
Study: 27231056

Group type: EXPERIMENTAL
Intervention: Supplemented group (200,000 IU of retinyl palmitate)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 24644139

Group type: EXPERIMENTAL
Intervention: Caffeinated energy shot
Number of subjects: 10

Group type: COMPARATOR
Intervention: Noncaffeinated energy shot
Number of subjects: 10
Study: 22575072

Group type: EXPERIMENTAL
Intervention: Low ED (consume ≥10 foods ≤1.0 kcal/g dietary ED and ≤2 foods ≥3.0 kcal/g dietary ED per day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-Energy, Low-Fat (1,200 to 1,500 kcal/day, ≤30% energy from fat)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-ED, Low-Energy, Low-Fat
Number of subjects: 44
Study: 19688393

Group type: EXPERIMENTAL
Intervention: Fundus-first method using ultrasonic dissection
Number of subjects: 243
Study: 17942381

Group type: EXPERIMENTAL
Intervention: Calcium therapy
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Hip T-score
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Fracture odds at zero T-score
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Prevalent fracture
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Unit fall in hip T-score
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Nomogram for fracture risk estimation
Number of subjects: 1098
Study: 16291885

Group type: EXPERIMENTAL
Intervention: Modafinil (200-400 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12016631

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 236
Study: 10561254

Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 220

Group type: COMPARATOR
Intervention: MAB
Number of subjects: 220
Study: 7745320

Group type: EXPERIMENTAL
Intervention: High tie of the inferior mesenteric artery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low tie of the inferior mesenteric artery
Number of subjects: 62
Study: 31740722

Group type: EXPERIMENTAL
Intervention: Tissue microarray scoring using DAKO 28‐8 immunohistochemistry assay
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Tissue microarray scoring
Number of subjects: 2008
Study: 28471973

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (VCV and PCV)
Number of subjects: 34
Study: 23264555

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 115
Study: 21496251

Group type: EXPERIMENTAL
Intervention: Intervention group participating in six, two-hour face-to-face sessions held over eight weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group.
Number of subjects: 0
Study: 19943976

Group type: EXPERIMENTAL
Intervention: Integrated care program combining patient-directed and workplace-directed interventions provided by a multidisciplinary team including a clinical occupational physician.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Role of the clinical occupational physician in the RTW process.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Time-investment as a barrier for implementation reported by the multidisciplinary team.
Number of subjects: 37
Study: 17982746

Group type: EXPERIMENTAL
Intervention: Inhalational Entonox
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous pethidine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Inhalational compressed air
Number of subjects: 150
Study: 15248189

Group type: EXPERIMENTAL
Intervention: Onofin-K (200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nizoral (200 mg)
Number of subjects: 24
Study: 11317474

Group type: EXPERIMENTAL
Intervention: 40 mg fluvastatin twice per day over a 3-month period (n = 14)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 21
Study: 9393270

Group type: EXPERIMENTAL
Intervention: BCAAs (Aminoleban EN) 100 g per day for 1 year
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 8194956

Group type: EXPERIMENTAL
Intervention: Smoking prevention programme integrated with other school subjects and parental involvement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control groups
Number of subjects: 0
Study: 3583472

Group type: EXPERIMENTAL
Intervention: Euphylong administered after a hot evening meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Euphylong administered before a cold evening meal
Number of subjects: 0
Study: 28401587

Group type: EXPERIMENTAL
Intervention: Get Busy Get Better (GBGB)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 208
Study: 27519921

Group type: EXPERIMENTAL
Intervention: NIV combined with HFNC (pressure support=10, PEEP=5, FiO2=100% + flow=60 L/min, FiO2=100%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: NIV alone (reference group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NIV combined with HFNC
Number of subjects: 50
Study: 24730354

Group type: EXPERIMENTAL
Intervention: Aerobic plus resistance training (AT + RT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 139
Study: 22502790

Group type: EXPERIMENTAL
Intervention: TAM 20 mg daily orally (arm A)
Number of subjects: 176

Group type: COMPARATOR
Intervention: TAM 10 mg daily starting simultaneously with bicalutamide (arm B)
Number of subjects: 176
Study: 20398868

Group type: EXPERIMENTAL
Intervention: Routine angiographic follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical follow-up alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-revascularized patients with nonischemic intermediate lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients who had TLR at angiographic follow-up
Number of subjects: 0
Study: 17869051

Group type: EXPERIMENTAL
Intervention: Two-session brief intervention (motivational enhancement therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3-month delayed-treatment control condition
Number of subjects: 40
Study: 16162709

Group type: EXPERIMENTAL
Intervention: Combined therapy (hyperpnea training + endurance training)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 29
Study: 12846760

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 14
Study: 10097506

Group type: EXPERIMENTAL
Intervention: Atarax (hydroxyzine) 50 mg daily for 28 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Atarax (hydroxyzine)
Number of subjects: 55
Study: 8762876

Group type: EXPERIMENTAL
Intervention: Classical acupuncture (experimental group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Superficial acupuncture (control group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (irradiated salivary glands)
Number of subjects: 38
Study: 1875413

Group type: EXPERIMENTAL
Intervention: Total doses D1, D2, D3, and D4 differing by increments of 4.8 Gy, with all patients receiving two fractions of 1.2 Gy each daily 5 days a week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen D3 (highest dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regimen D1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen D2 and D3
Number of subjects: 0
Study: 6653395

Group type: EXPERIMENTAL
Intervention: Low opiate use group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High opiate use group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study: 31751343

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate-oxytocin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Misoprostol-oxytocin
Number of subjects: 60
Study: 29122186

Group type: EXPERIMENTAL
Intervention: IMU-based inclinometer solutions
Number of subjects: 13

Group type: COMPARATOR
Intervention: Accelerometer-based inclinometers
Number of subjects: 13
Study: 26888208

Group type: COMPARATOR
Intervention: Bright white-light treatment (BLT, broad-wavelength light without UV 10,000 lux, irradiance 31.7 Watt/m(2))
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Narrow-band blue light (BLUE, 100 lux, irradiance 1.0 Watt/m(2))
Number of subjects: 48
Study: 24419823

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (3 cc)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corticosteroid injection (40 mg DepoMedrol)
Number of subjects: 40
Study: 22752379

Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging using indocyanine green (ICG) with 99(m) technetium-nanocolloid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Near-infrared fluorescence imaging using indocyanine green (ICG) with 99(m) technetium-nanocolloid and patent blue
Number of subjects: 24
Study: 20958144

Group type: EXPERIMENTAL
Intervention: e-Flow rapid(®) nebulizer
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sidestream(®) nebulizer used alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sidestream(®) nebulizer coupled to a 110‐mL corrugated piece of tubing
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All three nebulizers (e-Flow rapid(®), Sidestream(®) alone, and Sidestream(®) with tubing)
Number of subjects: 6
Study: 17211605

Group type: EXPERIMENTAL
Intervention: Local collagen-gentamicin prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine intravenous prophylaxis of isoxazolyl-penicillin
Number of subjects: 0
Study: 15167592

Group type: EXPERIMENTAL
Intervention: Ketoconazole (100 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no ketoconazole)
Number of subjects: 100
Study: 11411734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9582592

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8018462

Group type: EXPERIMENTAL
Intervention: (S)-flurbiprofen 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: (R)-flurbiprofen 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: (R)-flurbiprofen 100 mg
Number of subjects: 16